Picture of Dynavax Technologies logo

DVAX — Dynavax Technologies News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedMid CapHigh Flyer

Dynavax Technologies Corp expected to post a loss of 2 cents a share - Earnings Preview

* Dynavax Technologies Corp  DVAX.OQ   DVAX.O  is expected
to show
a rise in quarterly revenue when it reports  results on May 8
for the period ending March 31 2024
    * The Emeryville California-based  company is expected to
report a
17.2% increase in revenue to $54.976 million from $46.93 million
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Dynavax Technologies
Corp is
for a loss of 2 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Dynavax
Technologies Corp is $27.00​, above​ its last closing price
of $11.64. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.01       -0.01      0.00      Beat    100
 Sep. 30 2023  -0.01       -0.01      0.10      Beat    766.7
 Jun. 30 2023  -0.09       -0.09      0.03      Beat    132.7​
 Jan. 1 0001   -0.13       -0.13      -0.19     Missed  -43.4
 ​​Dec.        0.43        0.43       0.45      Beat    5.3
 31 2022                                                
 Jan. 1 0001   0.34        0.33       0.43      Beat    31.3​
 Jun. 30 2022  0.22        0.22       0.87      Beat    295.5
 Mar. 31 2022  0.24        0.24       0.22      Missed  -8.3
 This summary was machine generated May 7 at 02:05 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Dynavax Technologies

See all news